Cardiovascular Drugs Practice Questions

Q: Which of the following short-acting selective beta-blocker drugs is used in the management of arrhythmia?

Esmolol. **Explanation:** **Esmolol** is the correct answer because it is a **highly cardioselective (Beta-1)** blocker characterized by its **ultra-short duration of action**. It has a half-life of approximately **9 minutes** due to its rapid hydrolysis by **red blood cell esterases** (not plasma cholinesterase). This pharmacokinetic profile makes it the drug of choice for the emergency management of supraventricular tachyarrhythmias, perioperative tachycardia, and hypertensive emergencies where precise, minute-to-minute control is required. **Analysis of Incorrect Options:** * **Carvedilol (Option A):** A non-selective beta-blocker with additional **alpha-1 blocking** and antioxidant properties. It is primarily used in the long-term management of chronic heart failure and hypertension, not for acute arrhythmia control. * **Celiprolol (Option C):** A selective beta-1 blocker with **partial beta-2 agonist** activity (intrinsic sympathomimetic activity). It is unique because it also has vasodilator properties, but it is not short-acting. * **Bisoprolol (Option D):** A highly cardioselective beta-1 blocker with a long half-life. It is a mainstay in the management of stable chronic heart failure (as per the CIBIS trials) and hypertension, but it is not suitable for rapid-onset/offset emergency use. **High-Yield Pearls for NEET-PG:** * **Metabolism:** Esmolol is metabolized by **RBC esterases**; therefore, its action is independent of renal or hepatic function. * **Administration:** It is administered only via **intravenous (IV) infusion**. * **Clinical Use:** Preferred for controlling heart rate in **Atrial Fibrillation/Flutter** during surgery or in the ICU. * **Mnemonic:** Remember **"Esmolol is Extremely short-acting"** (9 minutes).

Q: Which antihypertensive drugs are beneficial or have a neutral role in lipid metabolism?

Prazosin and Losartan. **Explanation:** The impact of antihypertensive drugs on lipid profiles is a high-yield topic for NEET-PG, as clinicians must choose metabolic-friendly drugs for patients with co-existing dyslipidemia or diabetes. **1. Why Option A is Correct:** * **Prazosin (Alpha-1 Blockers):** These are unique among antihypertensives because they actually **improve** the lipid profile. They decrease LDL and triglycerides while increasing HDL (the "good" cholesterol). They also improve insulin sensitivity. * **Losartan (ARBs):** Angiotensin Receptor Blockers (ARBs) and ACE inhibitors are considered **metabolically neutral**. They do not adversely affect lipid levels or glucose tolerance, making them first-line choices in patients with metabolic syndrome. **2. Why Other Options are Incorrect:** * **Option B (Chlorthiazide):** Thiazide diuretics are notorious for causing **metabolic derangements**, including hyperlipidemia (increased LDL and VLDL) and hyperglycemia (impaired glucose tolerance). * **Option C (Propranolol):** Non-selective Beta-blockers (like Propranolol) generally have a negative impact on lipids. They can **increase triglycerides** and **decrease HDL** levels by inhibiting lipoprotein lipase. * **Option D (Furosemide):** Like Thiazides, Loop diuretics can cause a transient increase in serum cholesterol and triglycerides, although their effect is generally less pronounced than Thiazides. **Clinical Pearls for NEET-PG:** * **Lipid-Friendly:** Alpha-blockers (Prazosin), Calcium Channel Blockers (Amlodipine), and ACEIs/ARBs. * **Lipid-Unfriendly:** Thiazides and older Beta-blockers (Propranolol, Atenolol). * **Exception:** Vasodilating beta-blockers like **Carvedilol** and **Nebivolol** are generally metabolically neutral compared to Propranolol. * **Mnemonic:** "ACEs and ARBs are neutral; Alphas are beneficial."

Q: A 60-year-old man with rheumatic mitral stenosis and atrial fibrillation is being treated for a fast ventricular rate. While on treatment, he develops a regular pulse of 64 beats/min. Which of the following is the probable drug that the patient is receiving?

Digoxin. ### Explanation The correct answer is **Digoxin (Option B)**. **Mechanism and Clinical Reasoning:** In a patient with **Atrial Fibrillation (AF)**, the pulse is characteristically "irregularly irregular" because the AV node is bombarded by disorganized atrial impulses. When a patient on treatment for AF develops a **regular pulse**, it is a classic sign of **Digoxin Toxicity**. Digoxin increases vagal tone, slowing AV conduction to control the ventricular rate. However, at toxic levels, it can cause high-grade AV block (leading to a slow rate) combined with increased automaticity of the junctional or ventricular pacemakers. This results in a **regularized rhythm** (e.g., Junctional Tachycardia or accelerated idioventricular rhythm) despite the underlying AF. This phenomenon is often referred to as "regularization of the pulse" in AF. **Why Other Options are Incorrect:** * **Verapamil (CCB), Carvedilol, and Propranolol (Beta-blockers):** These drugs are used for rate control in AF by increasing the refractory period of the AV node. While they slow the heart rate, the rhythm remains **irregularly irregular** because they do not typically induce the junctional escape rhythms or complete heart block seen in digoxin toxicity. **High-Yield Clinical Pearls for NEET-PG:** * **ECG in Digoxin Toxicity:** The most common arrhythmia is **PVCs** (Bigeminy); the most characteristic/specific is **Atrial Tachycardia with AV block**. * **Electrolyte Triggers:** Hypokalemia, hypomagnesemia, and hypercalcemia predispose to digoxin toxicity. * **Drug Interactions:** Quinidine, Verapamil, and Amiodarone increase digoxin levels by displacing it from tissue binding sites or reducing renal clearance. * **Visual Side Effect:** Xanthopsia (yellowish-green vision).

Q: Which of the following anti-arrhythmic agents does not belong to class Ic?

Tocainide. ### Explanation The classification of anti-arrhythmic drugs is based on the **Vaughan-Williams Classification**, which categorizes drugs according to their primary mechanism of action on the cardiac action potential. **1. Why Tocainide is the Correct Answer:** **Tocainide** belongs to **Class Ib** anti-arrhythmics. Class Ib agents are weak sodium channel blockers that decrease the duration of the action potential and shorten the refractory period. They specifically bind to sodium channels in the inactivated state and dissociate rapidly. Other drugs in this class include Lidocaine and Mexiletine. **2. Analysis of Incorrect Options (Class Ic Agents):** Class Ic drugs are the most potent sodium channel blockers. They significantly decrease the slope of Phase 0 depolarization and have little to no effect on the action potential duration. * **Encainide:** A classic Class Ic agent (though largely discontinued due to pro-arrhythmic risks). * **Flecainide:** A prototype Class Ic drug used for supraventricular tachycardias (SVT) and atrial fibrillation in patients without structural heart disease. * **Propafenone:** A Class Ic agent that also possesses weak beta-blocking activity. **3. High-Yield NEET-PG Clinical Pearls:** * **Mnemonic for Class I:** "**D**ouble **P**yramids **Q**uickly" (Ia: Disopyramide, Procainamide, Quinidine); "**L**etters **M**ake **T**ext" (Ib: Lidocaine, Mexiletine, Tocainide); "**F**ries **P**lease **E**at" (Ic: Flecainide, Propafenone, Encainide). * **CAST Trial Warning:** The Cardiac Arrhythmia Suppression Trial (CAST) showed that Class Ic drugs (Flecainide/Encainide) increase mortality in patients with a history of myocardial infarction or structural heart disease. * **Class Ib Specificity:** These drugs are most effective in **ischemic tissues** because they bind preferentially to depolarized/inactivated sodium channels.

Q: Erectile dysfunction is commonly seen with which antihypertensive medication?

Atenolol. **Explanation:** **Correct Option: A. Atenolol** Erectile dysfunction (ED) is a well-documented side effect of **Beta-blockers**, particularly non-selective ones and older cardioselective agents like Atenolol. The mechanism is multifactorial: 1. **Reduced Penile Perfusion:** Beta-blockers decrease cardiac output and systemic blood pressure, reducing the pressure required for cavernous filling. 2. **Unopposed Alpha-1 Vasoconstriction:** By blocking Beta-2 receptors (even partially with cardioselective drugs at higher doses), Alpha-1 mediated vasoconstriction in the penile vasculature goes unopposed, hindering tumescence. 3. **CNS Effects:** They may also decrease libido through central sympathetic inhibition. **Analysis of Incorrect Options:** * **B. Prazosin:** This is an Alpha-1 blocker. Unlike Beta-blockers, Alpha-blockers are generally **not** associated with ED; in fact, they may improve erectile function by causing vasodilation. However, they are notorious for causing **retrograde ejaculation**. * **C. Nifedipine:** Calcium Channel Blockers (CCBs) are considered "sexually neutral" and are rarely associated with erectile dysfunction. * **D. Furosemide:** While loop diuretics can occasionally cause ED, the association is significantly weaker than with Thiazide diuretics (which are a common cause of ED) or Beta-blockers. **High-Yield Clinical Pearls for NEET-PG:** * **Most common antihypertensives causing ED:** Thiazide diuretics (e.g., Hydrochlorothiazide) and Beta-blockers (e.g., Atenolol, Propranolol). * **Exception among Beta-blockers:** **Nebivolol** is a unique Beta-blocker that increases Nitric Oxide (NO) release, often improving or having a neutral effect on erectile function. * **Preferred drugs in hypertensive patients with ED:** ACE inhibitors, ARBs (e.g., Losartan), and CCBs are generally preferred as they do not impair sexual function.

Q: All of the following are ECG changes seen in Digoxin toxicity except?

PR shortening. ### Explanation **Digoxin** has complex effects on the cardiac conduction system, primarily mediated through increased vagal tone and direct inhibition of the Na+/K+ ATPase pump. **Why PR shortening is the correct answer:** Digoxin **increases vagal (parasympathetic) tone**, which slows conduction through the Atrioventricular (AV) node. On an ECG, AV nodal delay is manifested as **PR interval prolongation**, not shortening. In cases of toxicity, this can progress to various degrees of heart block. **Analysis of Incorrect Options:** * **QT shortening (A):** Digoxin shortens the ventricular action potential duration and the refractory period, leading to a characteristic **shortened QT interval**. This is a classic finding. * **ST depression (C):** One of the most common signs of digoxin effect/toxicity is **ST-segment depression** with a unique morphology known as the "reverse tick," "scooped-out," or "Salvador Dali mustache" appearance. * **T wave inversion (D):** Digoxin causes changes in ventricular repolarization, frequently resulting in **T wave flattening or inversion**, often associated with the ST-segment changes mentioned above. **High-Yield Clinical Pearls for NEET-PG:** * **Most common arrhythmia in toxicity:** Ventricular Bigeminy. * **Most characteristic/specific arrhythmia:** Atrial Tachycardia with AV block. * **Electrolyte triggers:** Hypokalemia, Hypomagnesemia, and Hypercalcemia predispose to toxicity. * **Visual disturbance:** Xanthopsia (yellow-green halos around lights). * **Antidote:** Digoxin-specific antibody fragments (DigiFab).

Q: Which calcium channel blocker has the maximum effect on cardiac conduction?

Verapamil. **Explanation:** Calcium Channel Blockers (CCBs) are classified into two main categories based on their chemical structure and site of action: **Dihydropyridines** (acting primarily on vascular smooth muscle) and **Non-dihydropyridines** (acting primarily on the heart). **Why Verapamil is Correct:** Verapamil belongs to the **Phenylalkylamine** class. It has the highest affinity for the L-type calcium channels located in the **Sinoatrial (SA) and Atrioventricular (AV) nodes**. By blocking these channels, it significantly slows the rate of recovery of the channel, leading to a marked decrease in conduction velocity (negative dromotropy) and heart rate (negative chronotropy). Therefore, it has the **maximum effect on cardiac conduction** among all CCBs. **Analysis of Incorrect Options:** * **Phenylamine (A):** This is likely a distractor or a misspelling of Prenylamine (a legacy CCB). It does not possess the potent electrophysiological profile of Verapamil. * **Nifedipine (B):** A Dihydropyridine. It is a potent vasodilator with minimal effect on cardiac conduction at clinical doses. It often causes **reflex tachycardia** due to peripheral vasodilation. * **Diltiazem (D):** A Benzothiazepine. It occupies an intermediate position, affecting both vascular resistance and cardiac conduction. While it slows conduction, its effect is less potent than Verapamil. **NEET-PG High-Yield Pearls:** * **Drug of Choice:** Verapamil is used for the termination of **Paroxysmal Supraventricular Tachycardia (PSVT)**. * **Contraindication:** Never give Verapamil to a patient on **Beta-blockers** or those with **Heart Failure**, as it can lead to severe bradycardia or heart block due to additive cardiosuppressant effects. * **Side Effect:** Constipation is the most common side effect of Verapamil.

Q: A 69-year-old man with heart failure and paroxysmal atrial fibrillation is prescribed amiodarone for maintenance of sinus rhythm. Which of the following is a known characteristic of amiodarone?

An active metabolite. **Explanation:** Amiodarone is a unique Class III antiarrhythmic drug with a complex pharmacokinetic profile, making it a high-yield topic for NEET-PG. **Why Option C is Correct:** Amiodarone is extensively metabolized in the liver by the CYP3A4 enzyme. Its primary metabolite is **Desethylamiodarone (DEA)**. This metabolite is pharmacologically **active** and possesses electrophysiological properties similar to the parent drug, contributing significantly to its long-term therapeutic and toxic effects. **Analysis of Incorrect Options:** * **A. Excellent oral absorption:** While amiodarone is absorbed from the GI tract, its bioavailability is inconsistent and incomplete (ranging from 30% to 70%) due to significant first-pass metabolism. * **B. A short half-life:** Amiodarone is highly lipophilic and sequesters in tissues (fat, liver, lungs). It has an exceptionally **long elimination half-life**, typically ranging from **25 to 60 days**. This necessitates the use of loading doses. * **D. Few drug interactions:** Amiodarone is a potent **inhibitor** of several P450 enzymes (CYP2C9, CYP2D6, CYP3A4) and P-glycoprotein. It has numerous clinically significant interactions, most notably increasing the plasma concentrations of **Warfarin, Digoxin, and Statins**. **NEET-PG High-Yield Pearls:** * **Iodine Content:** Amiodarone is structurally related to thyroxine and contains 37% iodine by weight, leading to thyroid dysfunction (Hypothyroidism/Wolff-Chaikoff or Hyperthyroidism/Jod-Basedow). * **Adverse Effects:** Remember the "6 P's": **P**ulmonary fibrosis (most serious), **P**hotodermatitis (Blue-grey skin), **P**rolonged QT interval (though rarely causes Torsades), **P**eripheral neuropathy, **P**apillary deposits (corneal microdeposits), and **P**roximally-acting thyroid issues. * **Drug of Choice:** It is the preferred antiarrhythmic for patients with heart failure or structural heart disease.

Q: Which beta-blocker can be safely used in hepatic disease?

Esmolol. **Explanation:** The correct answer is **Esmolol (Option A)**. The primary medical concept here is the site of drug metabolism. **Why Esmolol is the correct choice:** Esmolol is a unique, ultra-short-acting $\beta_1$-selective blocker. Unlike most beta-blockers that undergo hepatic metabolism, Esmolol is rapidly hydrolyzed by **red blood cell (RBC) esterases**. Because its clearance is independent of liver or kidney function, it can be safely used in patients with hepatic failure without the risk of drug accumulation or toxicity. **Analysis of Incorrect Options:** * **Betaxolol (Option B):** This is a cardioselective beta-blocker that undergoes significant hepatic metabolism. It is not the preferred choice in liver disease. * **Bisoprolol (Option C):** Bisoprolol is balanced in its elimination (50% hepatic and 50% renal). While safer than purely hepatic drugs, it still requires caution and potential dose adjustment in severe liver disease compared to Esmolol. * **Carvedilol (Option D):** This is a non-selective beta and alpha-1 blocker that is **extensively metabolized by the liver**. It is contraindicated or requires extreme caution in patients with hepatic impairment due to a significant increase in bioavailability and half-life. **High-Yield Clinical Pearls for NEET-PG:** * **Esmolol Half-life:** Approximately **9 minutes**, making it ideal for "on-off" control during hypertensive emergencies or intraoperative tachycardia. * **Metabolism Fact:** Always remember "Esmolol = Esterases." This is a frequent examiner favorite. * **Propranolol:** It has high lipid solubility and undergoes extensive first-pass metabolism in the liver; it is the drug of choice for preventing variceal bleeding in portal hypertension but must be dosed carefully. * **Atenolol & Nadolol:** These are primarily **renally excreted** and are the drugs of choice when avoiding hepatic metabolism is necessary, though Esmolol remains the safest in acute settings.

Question 1

Which drug may aggravate renovascular hypertension?

Accepted Answer

ACE inhibitors

Answer

Beta blockers

Answer

Calcium channel blockers

Answer

Thiazide diuretics

Question 2

Which of the following short-acting selective beta-blocker drugs is used in the management of arrhythmia?

Accepted Answer

Esmolol

Answer

Carvedilol

Answer

Celiprolol

Answer

Bisoprolol

Question 3

Which antihypertensive drugs are beneficial or have a neutral role in lipid metabolism?

Accepted Answer

Prazosin and Losartan

Answer

Prazosin and Chlorthiazide

Answer

Propranolol

Answer

Furosemide

Question 4

A 60-year-old man with rheumatic mitral stenosis and atrial fibrillation is being treated for a fast ventricular rate. While on treatment, he develops a regular pulse of 64 beats/min. Which of the following is the probable drug that the patient is receiving?

Accepted Answer

Digoxin

Answer

Verapamil

Answer

Carvedilol

Answer

Propranolol

Question 5

Which of the following anti-arrhythmic agents does not belong to class Ic?

Accepted Answer

Tocainide

Answer

Encainide

Answer

Flecainide

Answer

Propafenone

Question 6

Erectile dysfunction is commonly seen with which antihypertensive medication?

Accepted Answer

Atenolol

Answer

Prazosin

Answer

Nifedipine

Answer

Furosemide

Question 7

All of the following are ECG changes seen in Digoxin toxicity except?

Accepted Answer

PR shortening

Answer

QT shortening

Answer

ST depression

Answer

T wave inversion

Question 8

Which calcium channel blocker has the maximum effect on cardiac conduction?

Accepted Answer

Verapamil

Answer

Phenylamine

Answer

Nifedipine

Answer

Diltiazem

Question 9

A 69-year-old man with heart failure and paroxysmal atrial fibrillation is prescribed amiodarone for maintenance of sinus rhythm. Which of the following is a known characteristic of amiodarone?

Accepted Answer

An active metabolite

Answer

Excellent oral absorption

Answer

A short half-life

Answer

Few drug interactions

Question 10

Which beta-blocker can be safely used in hepatic disease?

Accepted Answer

Esmolol

Answer

Betaxolol

Answer

Bisoprolol

Answer

Carvedilol

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?